A tumor-associated glycoprotein as a novel serological marker for pancreatic cancer: the confirmatory clinical study

A tumor-associated glycoprotein as a novel serological marker for pancreatic cancer: the confirmatory clinical study - A novel serological marker for pancreatic cancer

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000021938

Enrollment

180

Registered

2016-04-16

Start date

2016-04-07

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pancreatic cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) more than 20 years old and less than 90 years old (2) pancreatic cancer patients and IPMN patients newly diagnosed and previously untreated (3) all individuals classified as controls are diagnosed as chronic hepatitis or gastrointestinal diseases with being evaluated for non-pancreatic diseases.

Exclusion criteria

Exclusion criteria: (1) pancreatic cancer patients and IPMN patients previously treated (2) patients who were suffering from any kind of malignancies including pancreatic cancer (3) sever renal or liver dysfunction (4) individuals who did not accept informed consent (5) unsuitable individuals for this clinical study

Design outcomes

Primary

Measure	Time frame
Comparison of the area under the curve (AUC) of Reciever Operating Characteristic Curves (ROC curves) between IGFP and CA19-9	—

Countries

Japan

Contacts

Public ContactKeisuke Taniuchi

Kochi Medical School Hospital, Kochi University Department of Gastroenterology and Hepatology

ktaniuchi@kochi-u.ac.jp088-880-2339

Outcome results